The generation of resistant cell lines via continuous drug exposure would enable the elucidation of the mechanisms involved in resistance emergence, the identification of novel biomarkers to improve patients’ management, and, ultimately, the discovery of new treatment approaches for HER2-positive breast cancer patients. The gene discussed is ERBB2; the disease is breast cancer.